Want to see TSE:ZEN full AI Analyst Report?
ZEN Stock Chart & Stats
C$0.77
-C$0.04(-5.13%)
At close: 4:00 PM EDT
C$0.77
-C$0.04(-5.13%)
Day’s Range― - ―
52-Week RangeC$0.52 - C$1.50
Previous CloseN/A
Volume182.49K
Average Volume (3M)56.52K
Market Cap
C$77.24M
Enterprise ValueC$60.34M
Total Cash (Recent Filing)C$16.60M
Total Debt (Recent Filing)C$1.93M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding126,619,530
10 Day Avg. Volume95,340
30 Day Avg. Volume56,518
Financial Highlights & Ratios
PEG Ratio1.44
Price to Book (P/B)7.78
Price to Sales (P/S)459.28
P/FCF Ratio-13.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$2.70Price Target Upside250.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageModest leverage and meaningful equity provide Zentek with a financial cushion while it develops and commercializes its technologies. This reduces refinancing and solvency pressure over the next several months, although continued losses could gradually weaken that protection.
Multiple Monetization RoutesZentek’s model offers several potential ways to monetize its nanomaterials intellectual property rather than relying on one commercial mechanism. Product sales, licensing, and partner services could support broader commercialization and create operating flexibility if adoption develops.
Broad Technology ApplicationsThe company’s graphene and advanced-materials platform addresses several application areas, including coatings, corrosion protection, and antimicrobial or filtration uses. This breadth can expand the addressable opportunity and allow development efforts to target multiple industrial markets.
Bears Say
Very Weak Revenue TractionExtremely small and declining revenue indicates that Zentek has not yet demonstrated meaningful commercial scale. Weak top-line traction limits internally generated funding, reduces operating leverage, and makes the company more dependent on successful future commercialization.
Persistent UnprofitabilityOngoing net losses and deeply negative operating results show that the current business model has not reached sustainable profitability. Without a durable improvement in revenue or margins, continued losses may erode equity and constrain investment in product development.
Ongoing Cash BurnConsistently negative operating and free cash flow means Zentek is not yet self-funding its operations or development activities. Continued cash burn can reduce financial flexibility over the next several quarters and increase the importance of achieving commercialization milestones.
Zentek News
ZEN FAQ
What was Zentek’s price range in the past 12 months?
Zentek lowest stock price was C$0.52 and its highest was C$1.50 in the past 12 months.
What is Zentek’s market cap?
Zentek’s market cap is C$77.24M.
When is Zentek’s upcoming earnings report date?
Zentek’s upcoming earnings report date is Nov 16, 2026 which is in 28 days.
How were Zentek’s earnings last quarter?
Zentek released its earnings results on Aug 14, 2026. The company reported -C$0.018 earnings per share for the quarter.
Is Zentek overvalued?
According to Wall Street analysts Zentek’s price is currently Undervalued.
Does Zentek pay dividends?
Zentek does not currently pay dividends.
What is Zentek’s EPS estimate?
Zentek’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zentek have?
Zentek has 126,619,530 shares outstanding.
What happened to Zentek’s price movement after its last earnings report?
Zentek reported an EPS of -C$0.018 in its last earnings report. Following the earnings report the stock price went down -2.326%.
Which hedge fund is a major shareholder of Zentek?
Currently, no hedge funds are holding shares in TSE:ZEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zentek Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$2.70 (250.65% Upside)
C$2.70 (250.65% Upside)
Insider Transactions
Bought Shares
Worth C$33.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.65%
12-Months-Change
Fundamentals
Return on Equity
-70.73%
Trailing 12-Months
Asset Growth
60.59%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Zentek
Zentek Ltd. engages in the research and development of graphene and related nanomaterials in Canada. It owns 100% interest in the Albany Graphite project located in Northern Ontario, Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compound. In addition, it develops synthesize graphene, graphene oxide, and graphene quantum dots for applications of graphene. The company was formerly known as ZEN Graphene Solutions Ltd. and changed its name to Zentek Ltd. in October 2021. Zentek Ltd. was incorporated in 2008 and is headquartered in Thunder Bay, Canada.
ZEN Stock 12 Month Forecast
Average Price Target
C$2.70
▲(250.65% Upside)
Technical Analysis
Arch Biopartners
―
BioMark Diagnostics
―
Medexus Pharmaceuticals Inc
―
―
Sona Nanotech Inc
―